Company Information

ERIS LIFESCIENCES LTD.

NSE : ERISBSE : 540596ISIN CODE : INE406M01024Industry : Pharmaceuticals & DrugsHouse : Private
BSE882.6012.15 (+1.4 %)
PREV CLOSE ( ) 870.45
OPEN PRICE ( ) 865.75
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 8453
TODAY'S LOW / HIGH ( )862.00 886.15
52 WK LOW / HIGH ( )603.95 971
NSE883.6013.5 (+1.55 %)
PREV CLOSE( ) 870.10
OPEN PRICE ( ) 866.55
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 883.60 (1)
VOLUME 62936
TODAY'S LOW / HIGH( ) 860.05 886.45
52 WK LOW / HIGH ( )603.5 971.9
ChairmanAmit Indubhushan Bakshi
Managing DirectorAmit Indubhushan Bakshi
Company SecretaryMilind Talegaonkar
Non Executive Independent DirectorSujesh Vasudevan
Kalpana Unadkat
Prashant Gupta
Rajeev Dalal
Whole Time DirectorKrishnakumar Vaidyanathan
Inderjeet Singh Negi
Kaushal Shah
Incorporation Year : 25-01 2007

Registered Office :

Address : Shivarth Ambit, Plot No. 142/2,Ramdas Road, Off S B R,Near Swati Bungalows, Bodakdev Ahmedabad,
Gujarat-380054 .

Phone : 079 30451000 / 1001

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.